Loading...
Loading...
Idenix Pharmaceuticals,
Inc.
IDIX, a biopharmaceutical company engaged in the discovery and
development of drugs for the treatment of human viral diseases, today
announced a non-exclusive collaboration with Janssen Pharmaceuticals, Inc. for
the clinical development of all-oral direct-acting antiviral (DAA) HCV
combination therapies. The collaboration will evaluate combinations including
IDX719, Idenix's once-daily pan-genotypic NS5A inhibitor, simeprevir (TMC435),
a once-daily protease inhibitor jointly developed by Janssen and Medivir AB,
and TMC647055, a once-daily non-nucleoside polymerase inhibitor, boosted with
low dose ritonavir, being developed by Janssen.
Clinical development plans include an initial drug-drug interaction study to
begin in the first quarter of 2013, followed by phase II studies as agreed
between the companies, and pending approval from regulatory authorities. The
phase II program is expected to first evaluate the two-DAA combination of
IDX719 and simeprevir plus ribavirin for 12 weeks in treatment-naïve
HCV-infected patients. Subsequently, the companies plan to evaluate a
three-DAA combination of IDX719, simeprevir and TMC647055/r, with and without
ribavirin. The clinical trials will be conducted by Idenix. Both companies
retain all rights to their respective compounds under this agreement.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in